OS Therapies Incorporated (OSTX)

OS Therapies' stock price has been affected by persistent unprofitability and a Q3 2025 earnings miss, leading to a stock decrease since November 30, 2025. Regulatory progress for OST-HER2, including EMA's rolling review initiation, had a moderate positive market reaction. Analysts have maintained 'Buy' ratings with price targets between $17 and $20. The company's share price has been volatile, and Dr. Robert S. Langer was appointed to the strategic advisory board.

Information on demand seasonality for OS Therapies' products is not readily available. Demand is primarily driven by disease incidence, clinical efficacy, regulatory approvals, and market access, rather than seasonal patterns, as cancer treatment needs are generally continuous.

OS Therapies, Inc. (OSTX) is a clinical-stage biopharmaceutical company focused on developing treatments for osteosarcoma (OS) and other solid tumors. The company's pipeline includes OST-HER2, an immunotherapy for HER2-expressing cancers, and OST-tADC, a platform for delivering targeted therapies to solid tumors. OST-HER2 has received multiple designations from the FDA and EMA.

OS Therapies is based in Grasonville, Maryland, with corporate offices in the New York City and Washington Metropolitan areas. While primarily operating in the United States, the company is pursuing regulatory approvals in Europe and plans to initiate a Phase 3 trial in Australia in Q3 2026.

OS Therapies' brand reputation has been shaped by clinical progress and regulatory milestones. Positive attention has been received for advancements in clinical trials for OST-HER2 and FDA/EMA designations. The appointment of Dr. Robert S. Langer has enhanced scientific credibility. Challenges include persistent unprofitability, missed earnings expectations, and shareholder dilution.

OS Therapies, Inc. is owned by institutional shareholders, individual insiders, and retail investors. Institutional owners include Vanguard Group Inc and CM Management, LLC. Shalom Auerbach is the largest individual shareholder, while Paul A. Romness, Theodore F. Search, John Ciccio, Colin Goddard, and Robert Petit are other significant individual insider owners.